



Year-end report

---

20  
24

---

Prostatype Genomics AB

# Summary

## Second half of 2024

### 1 July – 31 December 2024

- Net sales amounted to 84 TSEK\* (908)
- EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -20,437 TSEK (-17,797)
- Cash flow from operating activities amounted to -21,499 TSEK (-9,938)
- Total cash flow for the period amounted to 7,620 TSEK (-9,269)
- Earnings per share\*\* amounted to -3.19 SEK (-174.76)

## Full year 2024

### 1 January 2024 – 31 December 2024

- Net sales amounted to 199 TSEK\* (1,356)
- EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -38 874 TSEK (-37 372)
- Cash flow from operating activities amounted to -44,709 TSEK (-29,138)
- Total cash flow for the period amounted to 6,686 TSEK (-8,793)
- Earnings per share\*\* amounted to -6.12 SEK (-346.85)

\* The order valued at approx. 1.8 MSEK from University Hospital Policlinico Tor Vergata in Rome, Italy, which was received in December 2024, is delivered and recognised as revenue in 2025.

\*\* Values for historic equity per share have been recalculated to reflect the reversed share split 1000:1 decided upon at the extraordinary general meeting on 22 October 2024.



## Significant events during the second half of 2024

### Significant regulatory and commercial progress in the United States

#### Submission of Medicare application for reimbursement in the United States

On September 30, it was announced that the company has submitted its application for the company's gene test Prostatype® to be approved for reimbursement by the Medicare healthcare system in the United States in line with the previously announced timeline. The application is submitted within the MoIDX program for molecular diagnostic tests. In practical terms, an approval means that the healthcare system will start to pay Prostatype Genomics a fixed sum, currently approx. 3,700 USD, per conducted test of Medicare-covered patients. Patients will thus not have to pay for the test themselves.

#### Business plan presented for the U.S. market

On October 28, the company presented the main features of its business plan for the genomic test Prostatype® in the U.S. market. In 2025, the goal is to forcefully strengthen and make visible the company's underlying value by achieving significant sales revenue and prove the product's scalability in carefully selected states and via groups of urologists (LUGPA groups). Once the scalability has been proven, the activities will be increased to a higher level to gradually claim a significant share of the addressable US market, which the company estimates at around 6 billion SEK (600 million USD) per year.

### Continued progress in the company's selected EMEA markets

#### Concrete commercial progress in Spain

On August 12, the company updated on concrete commercial progress in Spain following the presentation of positive data from a Spanish multicentre study with the genetic test Prostatype® in April. In August, agreements for enabling submission of biopsies to the company's partner Eurofins Megalab for Prostatype® testing had been signed with around ten private healthcare providers in the country, of which some had started to use the test commercially, and more have been signed continuously during the rest of the year.

#### Prostatype® can contribute to over 600 MSEK in annual health economy benefit in Sweden

On October 3, it was announced that a more extensive use of the company's gene test Prostatype® following diagnosed prostate cancer could contribute to just over 600 MSEK in annual health economic benefit in Sweden alone. This is according to a recent study by the Institute for Health and Healthcare Economics (IHE), which was presented at the Swedish Urological Association's annual meeting in Norrköping on October 3, 2024.

#### Prostatype Genomics obtains IVDR certification

On November 5, it was announced that the company has obtained certification in accordance with the EU regulation for medical devices for in vitro diagnostics (IVDR), following a comprehensive evaluation process by its notified body TÜV SÜD. The certification asserts that the company's operations within prognostic gene testing for diagnosed prostate cancer meet high standards in safety, quality and performance, and thus constitute an important regulatory milestone.

#### Breakthrough order from leading Italian urology centre valued at 1.8 MSEK

On December 3, it was announced that the company has received its largest order so far from University Hospital Policlinico Tor Vergata in Rome, Italy. The order comprises a low three-digit number of test kits for Prostatype®, the company's prognostic gene test used for diagnosed prostate cancer. The hospital laboratory where the tests will be analysed has been validated by the company, which means that testing of Italian patients can be initiated shortly.

The order value was initially approx. 1.3 MSEK and has since then been revised to approx. 1.8 MSEK. Delivery and payment will be conducted in partial deliveries during 2025, of which the first partial delivery was conducted in January.

## Capital raises and reverse split of shares

### The company's rights issue subscribed to a total of 79.8 percent

On September 3, it was announced that the company's rights issue was subscribed to 66.0 percent including subscription commitments, which meant that guarantee commitments of approximately 6.1 percent were activated. In addition, loans were converted to a value of 3.8 MSEK. In total, this meant that the rights issue was subscribed to approx. 79.8 percent, and thus that Prostatype Genomics was provided with approx. 35.7 MSEK before deduction for issue costs.

### Reverse split of shares and reduction of the company's share capital

On 22 October, an extraordinary general meeting resolved to consolidate the company's shares 1,000:1, meaning that 1,000 shares would be merged into 1 share. After the reverse split, the number of shares in the company amounted to 5,148,351. The reverse split was primarily carried out to achieve a more reasonable trading price for the company's shares.

At the same general meeting, it was resolved to reduce the company's share capital by 50,968,679.06 SEK for allocation to unrestricted equity. This meant that the share capital was reduced from 51,483,514.16 SEK to 514,835.10 SEK. At the same time, the quota value of the company's share increased from 0.01 SEK/share to 0.10 SEK/share.

### Subscription rate of approximately 93.6 percent for the company's TO 4 warrants

On December 10, it was announced that the subscription rate was 93.6 percent for the subscription of shares supported by the company's TO 4 warrants. This meant that 1,556,419 shares were subscribed for with the support of TO 4 warrants, and the company subsequently in 2025 carried out a directed issue of 130,443 shares to underwriters. In total, the company received approximately 9.8 MSEK before deduction for issue costs.

## Significant events after the end of the period

### The company's Medicare application for reimbursement in the U.S. is in the final phase

On January 3, it was announced that the processing of the company's application for the genomic test Prostatype® to be included in the federal U.S. healthcare program Medicare's reimbursement system is in the final phase. A small number of supplementary questions have been received, and the company is working to compile the answers, which will be submitted to Medicare shortly. The company has thus taken a major step towards completing the application and getting Prostatype® approved for reimbursement in the near future.

### Health economics study and complementary analysis show that Prostatype® can provide 800 MSEK in annual health economic benefit in Sweden

On February 10, Prostatype Genomics announced that the results from the health economics study with the company's prognostic genomic test Prostatype® had been published in the renowned scientific journal *Pharmacoeconomics*. The study and a complementary analysis, both conducted by the Institute for Health and Healthcare Economics (IHE), show that Prostatype® can contribute with just over 800 MSEK in annual health economic benefit just in Sweden compared to the method for risk classification of established prostate cancer that is currently being used in Sweden's healthcare system.

### Supplementary answers submitted in the final phase of the company's Medicare application for reimbursement in the U.S.

On February 13, it was announced that Prostatype Genomics has compiled and submitted supplementary answers in the final phase of its Medicare application to get the prognostic genomic test Prostatype® approved for reimbursement in the United States. The compilation has been conducted in an efficient manner together with external partners in Sweden and the United States to create optimal conditions to complete the application process and get Prostatype® approved for reimbursement in the near future.



## CEO Fredrik Rickman comments

**The second half of 2024, just like the first half of the year, was characterized by continued progress in the U.S. market. We are now getting increasingly closer to the point where the company's main challenges go from being regulatory and study related to being about how to scale up the U.S. sales to be able to reach breakeven and then generate profit in the most efficient way possible.**

To make it possible for our genomic test Prostatype® to start generating significant sales revenue in the U.S., the world's largest market for prognostic genomic tests, there are mainly three things that are needed: market entry, that the product is approved for reimbursement by the largest health insurance system Medicare, and that we are able to show sufficiently strong and scientifically proven performance to make a broad group of American urologists want to start using the product.

During the first half of the year, market entry was obtained, and in the end of September we submitted a Medicare application to get Prostatype® approved for reimbursement. At the same time the large U.S. study with Prostatype® conducted by the Veteran Affairs healthcare system progressed, and at the end of the year the absolute majority of the patients in the study had gone through the laboratory analyses needed to produce results.

In parallel, we are working with a growing number of selected American urologists at different urology centres who have started using Prostatype®, as a preparation to be able to start generating income for the company as

quickly as possible when our Medicare approval is achieved. This is promising from a sales perspective, as it clearly shows the potential of Prostatype® in the U.S. market.

Shortly after the end of the year, we were able to announce that our Medicare application had reach its final phase, as a number of supplementary questions had been received after the processing of the application. The questions were in line with what we expected, and we have today submitted answers which were compiled together with external experts. Even though we were not able to fully reach the target to obtain Medicare approval in Q4 2024, I want to emphasize that we are, and should be, very satisfied with the comprehensive progress that we have achieved in the United States in 2024. For a small Swedish life science company with limited resources, to now being close to a crucial breakthrough on a billion SEK market with a product that has strong clinically proven performance and an attractive Medicare reimbursement level for its product category, and this while receiving the full sales revenue instead of a partner collaboration that takes away around half of the income, is an achievement few have been able to accomplish.

“ We are now looking forward to the rest of 2025 with excitement. The next correspondence from Medicare will be highly interesting, as we believe that we have created optimal conditions for completing the application process and obtaining an approval in the near future.


---

In addition to the United States, I also want to highlight the company's progress in our selected EMEA markets in 2024. In Spain, we presented strong results from a multi-centre study, and since then more than 30 public and private healthcare providers have signed agreements to being able to submit biopsies for Prostatype® testing to our partner Eurofins Megalab, of which some have initiated their use of the product. The clinical study will be presented in a national Spanish scientific journal in the near future. And in Italy, we received a breakthrough order in December valued at approx. 1.8 MSEK from University Hospital Policlinico Tor Vergata in Rome. The company is already working to broaden the use of Prostatype® to other geographical regions in Italy. Additionally, the company obtained IVDR approval, an important regulatory milestone in Europe, in November. In Sweden, we presented a health economics study that together with a complementary analysis shows that a broad usage of Prostatype® can provide an annual health economic benefit of 800 MSEK in Sweden alone.

We are now looking forward to the rest of 2025 with excitement. The next correspondence from Medicare will be highly interesting, as we believe that we have created optimal conditions for completing the application process and obtaining an approval in the near future. At the same time, the U.S. study with Prostatype® is expected to be completed in February-March, and we will then present preliminary results which will be followed up with scientific articles and presentations at American and European conferences during the year. When we have received Medicare approval and completed the U.S. study, it should also become possible for the stock market to begin to value the company based on expected sales potential and profit, which is supported by the latest analyst report on the company by Aktiespararna.

Finally, I would like to thank all shareholder who contributed to our financing in 2024. We are working intensively towards realizing the significant values in the company, which have been built up over many years, at the same time as we continue to facilitate an improved prostate cancer care for the benefit of patients, their relatives and all relevant healthcare systems.

**Fredrik Rickman**  
 CEO Prostatype Genomics AB  
 Nacka Strand, 13 February 2025



# Key figures

## Group

TSEK	2024 July-Dec	2023 July-Dec	2024 Full year	2023 Full year
Net sales	84	908	199	1,356
EBITDA	-20,437	-17,797	-38,874	-37,372
Total Assets	41,970	49,222	41,970	49,222
Total Equity	33,469	24,674	33,469	24,674
Net cash flow	7,620	-9,269	6,686	-8,793
Equity/Assets-ratio	80%	50%	80%	50%
Number of employees EoP	6	6	6	5
Equity per share, SEK *	4.99	206.54	4.99	206.54
Earnings per share, SEK *				
- Before dilution	-3.19	-174.76	-6.12	-346.85
- After dilution	-3.19	-174.76	-6.12	-346.85
Number of shares at the end of the period	6,704,770	119,460,007	6,704,770	119,460,007
Number of shares at the end of the period after full dilution	6,704,770	119,460,007	6,704,770	119,460,007
Average number of shares for the period	2,048,622,457	119,460,007	1,410,722,766	80,820,327

\* Values for historic earnings and equity per share have been recalculated to reflect the reversed share split 1000:1 decided upon at the extraordinary general meeting on 22 October 2024.

## Definition of key ratios

Equity/debt ratio

Equity / total assets

Earnings per share

Net profit/loss for the year / number of shares by period closing

Diluted earnings per share

Net profit/loss for the year / (number of shares + warrants by period closing)

# Financial development

## Second half of 2024

### Net sales and results

Net sales for the first half of 2024 amounted to 84 TSEK (908). The group is still in the initial phase of commercialization, and thus the net sales is in line with expectations.

The operation profit/loss for the company (EBIT) amounted to -21,453 TSEK (-18,733). The company's costs mainly consist of research, testing, personnel and commercialization, with a stronger focus than before on preparations ahead of a U.S. launch.

Earnings per share for the period amounted to SEK -3.19 (174.76) where recalculation was made to reflect the 1000:1 reverse share split that was carried out during the second half of 2024.

### Investments

The investments mainly relate to product development in and towards the United States and amount to a total of 1,822 TSEK (7,763).

### Cash flow and liquid assets

The cash flow during the period amounted to 7,620 TSEK (8,432). The group's cash and cash at the end of the period amounted to 9,420 TSEK (2,682).

### The parent company

The parent company's income and operating result for the period amounted to 149 TSEK (967) and -14,881 TSEK (-14,995), respectively. The company invested 1,436 TSEK (5,720) mainly in product development and financed subsidiaries with 5,506 TSEK (6,034). Net cash flow amounted to 7,721 TSEK (-9,606) and cash and cash equivalents at the end of the period amounted to 9,302 TSEK (2,069).

## Full year 2024

### Net sales and result

Net sales amounted to 199 TSEK (1,356). The company is still in the initial phase of commercialization, and thus the net sales is in line with expectations.

The operating result for the period (EBIT) amounted to -40,853 TSEK (-39,247). The company's costs mainly consist of research, testing, personnel and commercialization.

Earnings per share for the period amounted to -6.12 SEK (346.86), where recalculation was made to reflect the 1000:1 reverse share split that was carried out during the second half of 2024.

### Investments

Investments relate primarily to product development in and towards the United States and amount to a total of SEK 8,356 thousand (8,566).

### Cash flow and liquid assets

Net cash flow during the period amounted to 6,686 TSEK (-8,793). The Group's cash and cash equivalents at the end of the period amounted to 9,420 TSEK (2,682).

### The parent company

The parent company's income and operating result for the period amounted to 264 TSEK (1,414) and -30,029 TSEK (-32,845), respectively. The company invested 4,594 TSEK (5,799) mainly in product development and financed subsidiaries with 11,455 TSEK (9,760). Net cash flow amounted to 7,233 TSEK (-9,420) and cash and cash equivalents at the end of the period amounted to 9,302 TSEK (2,069).



## The share

The company's share is listed on the NASDAQ First North Growth Market under the symbol PROGEN, and it is traded with ISIN code SE0023261532 since October 31, 2024.

On 31 December 2024, the share capital amounted to 670,477 SEK (7,167,600) distributed over 6,704,770 shares (119,460,007). The decreases, despite new share issues during the year, are due to the fact that the Company at the extraordinary general meeting on 22 October 2024 resolved to conduct a 1000:1 reverse share split and to reduce the share capital. Before the reverse share split, the share was traded with the ISIN code SE0014684569. All shares are issued and fully paid.

After the end of the period, an underwriter and compensation issue of a total of 130,433 shares was completed, and the share capital increased by a total of 13,044 SEK. At the time of publication of the report, the number of shares and share capital amounted to 6,835,213 shares and 683,521 SEK, respectively.

A list of the largest shareholders can be found on the company's website ([www.prostatypegenomics.com](http://www.prostatypegenomics.com)).

## The balance sheet

At the end of the period, the group has intangible fixed assets of SEK 29,267 TSEK (23,180) and cash and cash equivalents of 9,420 TSEK (2,682). The group's equity amounts to 33,469 TSEK (24,674) and outstanding loans amount to 67 TSEK (11,667).

The group's intangible assets mainly represent values for expenses, development work and patents regarding the company's product. Development expenses and patents are written off on a straight-line basis over 10 years.

## Liquidity, financing, capital requirements

### Liquidity

During the summer months of 2024, the Group had a strained liquidity in anticipation of the rights issue which was then carried out in September 2024. The rights issue and the subsequent series TO4 warrant have provided the Group with liquidity for some time into 2025.

### Financing

The Group has almost no external debt financing left. The growth loan from Almi, which at the end of the period amounted to 67 TSEK, will be fully amortized on February 28, 2025.

### Capital requirements

As previously announced, the Group will now require growth financing to continue operations according to the current business plan.

The Board is actively working on various alternatives for financing in the short and long term and the report is prepared based on the assumption of continued operation. In the event that additional financing is not obtained, the Group may lack the liquidity required to continue its operations over the next 12 months.

## Forward-looking statements

Certain statements in this report are forward-looking and actual results may differ materially. In addition to the factors discussed, other factors may have an impact on actual outcomes. Such factors include developments for customers, competitors, effects of economic and market conditions, national and international laws and regulations, tax regulations, fluctuations in exchange rates and interest rates and political risks.



# Profit & loss

## Consolidated income statement in summary

TSEK	2024 July-Dec	2023 July-Dec	2024 Full year	2023 Full year
Net sales	84	908	199	1,356
Own work capitalized	386	1,759	1,719	2,372
Other operating income	0	59	65	59
<b>Total income</b>	<b>469</b>	<b>2,726</b>	<b>1,983</b>	<b>3,787</b>
Research and development cost	-1,231	-1,174	-2,211	-3,225
Other external costs	-11,539	-9,505	-22,355	-19,832
Staff cost	-7,812	-9,864	-15,709	-18,102
Depreciation and impairment of tangible and intangible fixed assets	-1,016	-937	-1,979	-1,875
Other operating expenses	-324	20	-583	0
<b>Total operating costs</b>	<b>-21,922</b>	<b>-21,459</b>	<b>-42,836</b>	<b>-43,034</b>
<b>Operating profit/loss (EBIT)</b>	<b>-21,453</b>	<b>-18,733</b>	<b>-40,853</b>	<b>-39,247</b>
Interest income and similar items	42	4	43	4
Interest expense and similar items	-850	-1,495	-1,677	-1,540
Currency effects	875	-652	1,436	-652
<b>Profit/loss after financial items</b>	<b>-21,386</b>	<b>-20,877</b>	<b>-41,051</b>	<b>-41,435</b>
Current tax	-	-	-	-
<b>Net profit/loss for the period</b>	<b>-21,386</b>	<b>-20,877</b>	<b>-41,051</b>	<b>-41,435</b>

# Balance

## Consolidated balance sheet in summary

TSEK	2024-12-31	2023-12-31
<b>ASSETS</b>		
Non-current intangible assets	29,267	23,180
Non-current tangible assets	312	60
Non-current financial assets	566	72
<b>Total non-current assets</b>	<b>30,145</b>	<b>23,312</b>
Inventory	95	203
Other current receivables	1,785	1,531
Subscribed but not paid-up rights issue	525	21,493
Cash and bank	9,420	2,682
<b>Total current assets</b>	<b>11,825</b>	<b>25,910</b>
<b>Total assets</b>	<b>41,970</b>	<b>49,222</b>
<b>Equity and liabilities</b>		
Share capital	670	7,168
Other capital	183,687	177,153
Other equity including net profit/loss for the period	-150,888	-159,647
<b>Total equity</b>	<b>33,469</b>	<b>24,674</b>
Non-current liabilities	-	67
Current liabilities	8,501	24,482
<b>Total liabilities</b>	<b>8,501</b>	<b>24,548</b>
<b>Total equity and liabilities</b>	<b>41,970</b>	<b>49,222</b>
Pledged securities	3,614	3,612
Contingent liabilities	-	-

# Cash

## Consolidated cash flow statement in summary

TSEK	2024 July-Dec	2023 July-Dec	2024 Full year	2023 Full year
Profit/loss after financial items	-21,386	-20,877	-41,051	-41,435
Adjustments for items not included in cash flow etc.	516	1,585	916	2,474
<b>Cash flow from operating activities before changes in working capital</b>	<b>-20,869</b>	<b>-19,292</b>	<b>-40,135</b>	<b>-38,961</b>
Change in inventory	106	90	109	-21
Change in operating receivables	-584	1,614	-244	980
Change in operating liabilities	-152	7,650	-4,439	8,864
<b>Changes in working capital</b>	<b>-629</b>	<b>9,354</b>	<b>-4,574</b>	<b>9,823</b>
<b>Cash flow from operating activities</b>	<b>-21,499</b>	<b>-9,938</b>	<b>-44,709</b>	<b>-29,138</b>
Investments in intangible assets	-1,052	-7,763	-7,578	-8,487
Investments in tangible assets	-285	-	-285	-75
Change in financial assets	-485	-	-493	-4
<b>Cash flow from investment activities</b>	<b>-1,822</b>	<b>-7,763</b>	<b>-8,356</b>	<b>-8,566</b>
Share issue proceeds, net	36,766	-2,568	66,151	18,111
Loans raised	-	11,200	8,825	16,200
Loans amortized	-5,825	-200	-15,225	-5,400
<b>Cash flow from financing activities</b>	<b>30,941</b>	<b>8,432</b>	<b>59,751</b>	<b>28,911</b>
<b>Cash flow for the period</b>	<b>7,620</b>	<b>-9,269</b>	<b>6,686</b>	<b>-8,793</b>
Cash and cash equivalents at the beginning of the period	1,785	11,972	2,682	11,489
Exchange differences cash and cash equivalents	15	-21	52	-13
<b>Cash and cash equivalents at the end of the period</b>	<b>9,420</b>	<b>2,682</b>	<b>9,420</b>	<b>2,682</b>

# Equity

## Consolidated changes in equity in summary

TSEK	Share capital	Other capital/ premium reserves	Other equity including net profit/loss for the year	Total equity
<b>Opening balance 2023-01-01</b>	<b>1,372</b>	<b>149,318</b>	<b>-124,539</b>	<b>26,151</b>
Reduction of share capital	-	-5,973	5,973	-
New share issues	5,796	18,206	-	24,002
Net share issues, subscribed not paid-up	-	24,992	-	24,992
Issue expenses	-	-9,391	-	-9,391
Exchange differences	-	-	354	354
Profit/loss for the period	-	-	-41,435	-41,435
<b>Closing balance 2023-12-31</b>	<b>7,168</b>	<b>177,153</b>	<b>-159,647</b>	<b>24,674</b>
<b>Opening balance 2024-01-01</b>	<b>7,168</b>	<b>177,153</b>	<b>-159,647</b>	<b>24,674</b>
Reduction of share capital	-56,942	5,973	50,969	-
New share issues	50,445	11,033	-	61,478
Net share issues, subscribed not paid-up	-	13	-	13
Issue expenses	-	-10,486	-	-10,486
Exchange differences	-	-	-1,158	-1,158
Profit/loss for the period	-	-	-41,051	-41,051
<b>Closing balance 2024-12-31</b>	<b>670</b>	<b>183,687</b>	<b>-150,888</b>	<b>33,469</b>

The share capital of 683,521 SEK is distributed over 6,835,213 shares.

# Parent company

## Parent company condensed financial statements

### Income statement

TSEK	2024 Jan-Jul	2023 Jan-Jul	2023 Full year	2022 Full year
Income	149	967	264	1,414
Operating expenses	-14,067	-15,025	-28,395	-32,384
Depreciation, amortization and impairment	-963	-937	-1,899	-1,875
<b>Operating profit/loss</b>	<b>-14,881</b>	<b>-14,995</b>	<b>-30,029</b>	<b>-32,845</b>
Financial items	-11,304	-1,670	-11,021	-1,714
<b>Profit/loss after financial items</b>	<b>-26,185</b>	<b>-16,664</b>	<b>-41,051</b>	<b>-34,559</b>
Taxes	-	-	-	-
<b>Net profit/loss for the period</b>	<b>-26,185</b>	<b>-16,664</b>	<b>-41,051</b>	<b>-34,559</b>

### Balance sheet

TSEK	2024-12-31	2023-12-31
Non-current assets	33,024	29,823
Current assets excl. cash and cash equivalents	6,800	23,692
Cash and cash equivalents	9,302	2,069
<b>Total Assets</b>	<b>49,126</b>	<b>55,584</b>
Equity	41,150	31,196
Non-current liabilities	-	-
Current liabilities	7,975	24,321
<b>Total equity and liabilities</b>	<b>49,126</b>	<b>55,584</b>

### Cash flow statement

TSEK	2024 Jan-Jul	2023 Jan-Jul	2023 Full year	2022 Full year
Cash flow from operating activities	-16,278	-6,284	-36,470	-22,772
Cash flow from investing activities	-6,942	-11,754	-16,048	-15,559
Cash flow from financing activities	30,941	8,432	59,751	28,911
<b>Cash flow for the period</b>	<b>7,721</b>	<b>-9,606</b>	<b>7,233</b>	<b>-9,420</b>
Cash balance at the end of the period	9,302	2,069	9,302	2,069

### Changes in equity

TSEK	Share capital	Other restricted capital	Development fund	Share Premium	Profit/loss brought forward	Total
<b>Opening balance 2023-01-01</b>	<b>1,372</b>	<b>-</b>	<b>16,710</b>	<b>149,318</b>	<b>-141,249</b>	<b>26,151</b>
New share issues	-	-5,973	-	-	5,973	-
Reduction of share capital	5,796	-	-	18,206	-	24,002
Net share issues, subscribed not paid-up	-	6,248	-	18,744	-	24,992
Issue expenses	-	-	-	-9,391	-	-9,391
Change in development fund	-	-	-1,857	-	1,857	-
Profit/loss for the period	-	-	-	-	-34,559	-34,559
<b>Closing balance 2023-12-31</b>	<b>7,168</b>	<b>275</b>	<b>14,853</b>	<b>176,878</b>	<b>-167,978</b>	<b>31,196</b>
New share issues	50,445	-6,248	-	17,281	-	61,478
Reduction of share capital	-56,942	5,973	-	-	50,969	-
Net share issues, subscribed not paid-up	-	13	-	-	-	13
Issue expenses	-	-	-	-10,486	-	-10,486
Change in development fund	-	-	-1,857	-	1,857	-
Profit/loss for the period	-	-	-	-	-41,051	-41,051
<b>Closing balance 2024-12-31</b>	<b>670</b>	<b>13</b>	<b>12,996</b>	<b>183,674</b>	<b>-156,203</b>	<b>41,150</b>

# General information

## Company information

Prostatype Genomics AB with organization number 556726-0285 is a limited company registered in Sweden, domiciled in Stockholm. The address is Augustendalsvägen 20, SE-131 52 Nacka Strand.

The company is engaged in the research and developments of medical devices and the sales of these.

Prostatype® is the result of more than fifteen years of research into the genomics of prostate cancer. The company was founded in 2007 as a spin off from Cancer Center Karolinska (Karolinska Institutet, Stockholm). The result was the development of the today CE-marked and market ready product Prostatype® Test System. Prostatype® is a test for diagnosis and prognosis that has been developed to provide the complementary information that is often needed for the selection of the optimal treatment strategy for each patient. The test analyzes the gene expression in cancer cells from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed. Aided by AI (Artificial Intelligence) technology, the gene test of Prostatype Genomics makes it possible to make a better prognosis and to classify the patient's illness into different risk types. In that way the company can reduce the risk of over- or under treatment, which in many cases lead to great discomfort for the patient. Prostatype® is today the only genetic test for prostate cancer that is available in kit format. The product is also very scalable in terms of volume due to the algorithm that forms the basis of the test.

All figures in the report are in thousands of Swedish kronor (TSEK) if not otherwise specified. Amounts or information in parentheses refer to the corresponding period of the previous year. Rounding differences may therefore occur.

## Accounting principles

The report has been prepared in accordance with BFNAR 2012:1 Årsredovisning och koncernredovisning (K3) issued by the Swedish Accounting Standards Boards (BFN). The accounting policy for the company complies with applied accounting principles for the most recent published annual report.

## Transactions with related parties

### Shareholder loan

During the first half of 2024, the company signed a loan agreement with JDS Invest AB, where board member Håkan Englund is chairman. The loan of 2 MSEK was signed at market terms. All loans från JDS Invest AB have been converted entirely to shares in the Company during the second half of 2024.

During the year, JDS Invest AB has received interest of 215 TSEK (57) in total.

### Consultancy fees

The company procures services for web-based solutions for P-score from SecureAppbox AB, where Håkan Englund is chairman of the board. During the year, services for 630 TSEK (396) were procured. Håkan Englund has not been involved in the procurement of these services.

Board member Mattias Prage is employed at Advokatbyrån Lindahl KB, which the company engages for advice on legal issues and company administration. During the year, Lindahl invoiced the company 1,036 TSEK (1,321).

Johan Waldhe, who has been a board member since the 2024 annual general meeting, is CEO of the communications and consulting company Honeybadger AB. During the year, services for 1,844 TSEK (-) have been procured.

## Material risks and uncertainties in summary

A description of the most significant market and business related risks can be found in the annual report for 2023, as well as in the prospectus submitted and published on the company's website [www.prostatypegenomics.com](http://www.prostatypegenomics.com)

### Valuation of assets

The company's product, Prostatype®, is in a commercialization phase. In addition to the short-term financial risk above, there is, as with all businesses, a long-term risk that objectives will not be achieved within the time frame on which the group's forecasts are based. If the sales do not reach the set goals so that the assumed cash flows do not occur at the rate assumed by the board and company management or are alternatively postponed further in time, or if other assumptions that formed the basis of the impairment test carried out by the company management would change in a negative way, this may lead to the intangible assets being written down at a faster rate than planned.





# Other information

## Financial calendar

Annual report 2024:	2025-04-24
Annual general meeting 2025:	2025-05-22
Interim report H1 2025:	2025-07-23
Year-end report 2025:	2026-02-12

The company's financial reports are available on [prostatypegenomics.com](http://prostatypegenomics.com)

### Review

This interim report has not been subject to review by the company's auditors.

### Certified Advisor

Carnegie Investment Bank AB (publ)  
+46 (0)73 856 42 65  
[certifiedadviser@carnegie.se](mailto:certifiedadviser@carnegie.se)

### Publication

This information is such information that Prostatype Genomics AB is obliged to make public according to the EU's market abuse regulation. The information was submitted, through the contact person below, for publication on 13 February, 2025.

Fredrik Rickman, CEO  
[fredrik.rickman@prostatypegenomics.com](mailto:fredrik.rickman@prostatypegenomics.com)

## Signing of the report

The board and the CEO assure that the year-end report provides a fair overview of the group's and the parent company's operations, balance and results, and describes the significant risks and uncertainty factors that the group is facing.

Nacka Strand, 13 February, 2025

---

Anders Lundberg  
Chairman

---

Håkan Englund  
Board member

---

Michael Häggman  
Board member

---

Mattias Prage  
Board member

---

Jörgen Dahlström  
Board member

---

Johan Waldhe  
Board member

---

CEO  
Fredrik Rickman

Phone: +46 (0)8-20 87 00  
Website: [www.prostatypegenomics.com](http://www.prostatypegenomics.com)



**Prostatype Genomics AB**

Augustendalsvägen 20, SE-131 52 Nacka Strand

Phone: +46 (0)8-20 87 00

Website: [www.prostatypegenomics.com](http://www.prostatypegenomics.com)